


#### **Amendments to the Claims:**

1. (Original) A compound corresponding to formula (I) below:



in which:

AP represents an active principle capable of acting on a biological target:

x represents an integer chosen from 0 and 1;

X represents a peptide chain comprising from 1 to 5 amino acids;

$\text{AA}_1$ ,  $\text{AA}_2$  and  $\text{AA}_3$ , which may be identical or different, each represent an amino acid;  $a_2$  and  $a_3$ , which may be identical or different, each represent an integer chosen from 0

and 1;

R represents a group chosen from:

- any molecule capable of being recognized by the target of the active principle AP, and

- a hydrophilic agent for modulating the HLB balance of the molecule of formula (I), R being chosen from monosaccharides, aminated derivatives of sugars, polysaccharides, natural or synthetic hormones, peptides, antibodies, polyethers and polyols,


Y represents a fluorinated C<sub>4</sub>-C<sub>12</sub> hydrocarbon-based chain containing a group  $\text{--}\overset{\text{O}}{\underset{\text{C}}{\parallel}}\text{--NH--}$ ,

-O-CO-NH-, S or O that allows its attachment either to one of the ends of the peptide chain [AA<sub>3</sub>]<sub>a3</sub>-[AA<sub>2</sub>]<sub>a2</sub>-[AA<sub>1</sub>], or to the side chain of one of the amino acids AA<sub>1</sub>, AA<sub>2</sub> or AA<sub>3</sub>;

the linkage between AP-(X)<sub>x</sub> and the chain [AA<sub>3</sub>]<sub>a3</sub>-[AA<sub>2</sub>]<sub>a2</sub>-[AA<sub>1</sub>] occurring via the side chain of one of the amino acids AA<sub>1</sub>, AA<sub>2</sub> or AA<sub>3</sub> or at the end of the peptide chain.

2. (Currently Amended) The compound as claimed in claim 1, characterized in that wherein the active principle is chosen from those that have anticancer activity, or free-radical scavenger, anti-inflammatory, antiseptic, analgesic, neuroleptic or antifungal activity.

3. (Currently Amended) The compound as claimed in Claim 1, wherein either one of claims 1 and 2, characterized in that the active principle is a linear, branched or cyclic molecule containing from 1 to 30 carbon atoms, one or more unsaturations, in particular one or more aromatic rings, and one or more functions chosen from: -O-, -S-, -OH, -SH, -Cl, -F, -Br,



4. (Currently Amended) The compound as claimed in Claim 1, wherein ~~any one of claims 1 to 3, characterized in that the amino acid attached to AP-(X)<sub>x</sub>- or to Y via its side chain is chosen from those containing an acid, amide, amine, thiol or alcohol function on their side chain.~~

5. (Currently Amended) The compound as claimed in Claim 1, wherein any one of claims 1 to 4, characterized in that the spacer arm X comprises 1 to 3 amino acids.

6. (Currently Amended) The compound as claimed in Claim 1, wherein any one of claims 1 to 5, characterized in that R is a peptide chosen from antibody fragments or epitopes having a pronounced affinity for the AP's biological target.

7. (Currently Amended) The compound as claimed in claim 6, which characterized in that it contains at least one peptide sequence chosen from the Arg-Gly-Asp sequence.


8. (Currently Amended) The compound as claimed in Claim 1, wherein any one of claims 1 to 7, characterized in that R consists of a poly(ethylene oxide) chain comprising from 5 to 30 ethylene oxide units or of a polyol consisting of an alkyl chain comprising from 4 to 16 carbon atoms and from 4 to 16 hydroxyl groups.

9. (Currently Amended) The compound as claimed in any one of claims 1 to 8, characterized in that Claim 1, wherein R is chosen from: glucose, fructose, mannose, galactose, ribose, glucosamine, lactose, cellobiose, maltose, lactobionamide and sucrose.

10. (Currently Amended) The compound as claimed in any one of claims 1 to 9, characterized in that Claim 1, wherein at least one of the spacer arms X, of the peptide chain  $[AA_3]_{a3}-[AA_2]_{a2}-[AA_1]$  and of R contains at least one tyrosine residue.

11. (Currently Amended) The compound as claimed in any one of claims 1 to 10, characterized in that Claim 1, wherein the fluorinated hydrocarbon-based chain Y is chosen from those corresponding to the formula A-Y' in which A represents a group chosen from:  $\text{C}=\text{O}$ , -NH-, -O-CO-NH-, S and O and Y' represents a molecule corresponding to the formula  $-(\text{CH}_2)_t-(\text{CF}_2)_r\text{F}$ , in which r and t represent two integers with:  $12 \geq r+t \geq 4$ .

12. (Original) A biologically active molecule comprising a fragment of formula (II):



in which x represents an integer chosen from 0 and 1;

X represents a peptide chain comprising from 1 to 5 amino acids;

AA<sub>1</sub>, AA<sub>2</sub> and AA<sub>3</sub>, which may be identical or different, each represent an amino acid;


a<sub>2</sub> and a<sub>3</sub>, which may be identical or different, each represent an integer chosen from 0 and 1;

R is chosen from monosaccharides, aminated derivatives of sugars, polysaccharides, polyethers, polyols, peptides, natural or synthetic hormones, and antibodies;

Y represents a fluorinated C<sub>4</sub>-C<sub>12</sub> hydrocarbon-based chain containing a group  $\text{--C}=\text{O}-\text{NH}$ ,

-O-CO-NH-, S or O that allows its attachment either to one of the ends of the peptide chain [AA<sub>3</sub>]<sub>a3</sub>-[AA<sub>2</sub>]<sub>a2</sub>-[AA<sub>1</sub>], or to the side chain of one of the amino acids AA<sub>1</sub>, AA<sub>2</sub> or AA<sub>3</sub>, and at least one of the spacer arms X, of the peptide chain [AA<sub>3</sub>]<sub>a3</sub>-[AA<sub>2</sub>]<sub>a2</sub>-[AA<sub>1</sub>] and of R contains at least one tyrosine residue.

13. (Currently Amended) The compound as claimed in Claim 1, any one of claims 1 to 9, characterized in that it corresponds corresponding to formula (Ia):



in which:

Su represents a group chosen from a monosaccharide, an aminated monosaccharide derivative, a polysaccharide, a polyol or a polyether;

AA<sub>1</sub> represents an amino acid carrying an acid, amine, alcohol or thiol function on its side chain, by means of which it is attached either to (X)<sub>x</sub>-AP or to Y; AA<sub>1</sub> is attached to Su and either to (X)<sub>x</sub>-AP, or to Y, via its N- and C-terminal ends;

AP represents an active principle capable of acting on a biological target;

x represents an integer chosen from 0 and 1;

X represents a peptide chain comprising from 1 to 5 amino acids;

Y represents a fluorinated C<sub>4</sub>-C<sub>12</sub> hydrocarbon-based chain containing a function chosen from  $\text{O}-\text{C}-\text{NH}$ , -O-CO-NH-, S and O that allows its attachment either to one of the ends of the amino acid AA<sub>1</sub>, or to the side chain of AA<sub>1</sub>.


14. (Currently Amended) The compound as claimed in claim 13, characterized in that wherein one or more of the conditions below are verified:

- Su represents a monosaccharide or a polysaccharide;
- X represents a spacer arm that is peptide in nature, containing at least one tyrosine residue;
- AA<sub>1</sub> represents an amino acid chosen from arginine and lysine;

- Y represents a fluorinated C<sub>6</sub>-C<sub>12</sub> hydrocarbon-based chain containing from 5 to 23 fluorine atoms, attached to the amino acid AA<sub>1</sub> via an -NH- function.

15. (Currently Amended) The compound as claimed in claim 14, characterized in that wherein the active principle is chosen from molecules capable of blocking the angiogenic process, in particular thalidomide.


16. (Currently Amended) The compound as claimed in claim 15, characterized in that it corresponds corresponding to formula A:




Molecule A

17. (Currently Amended) The compound as claimed in claim 15, characterized in that wherein the active principle AP is chosen from free-radical scavengers, in particular N-benzylidene-tert-butylamine oxide derivatives.

18. (Currently Amended) The compound as claimed in claim 17, characterized in that it corresponds corresponding to formula E:



19. (Currently Amended) The compound as claimed in claim 12, characterized in that it corresponds corresponding to formula (Ib):



in which:


AA<sub>1</sub> represents an amino acid carrying an acid, amine, alcohol or thiol function on its side chain,

Y represents a fluorinated C<sub>4</sub>-C<sub>12</sub> hydrocarbon-based chain containing a function chosen from  $\text{C}=\text{O}$ , -NH, -O-CO-NH-, S and O that allows its attachment either to one of the ends of the amino acid AA<sub>1</sub>, or to the side chain of AA<sub>1</sub>,

Pep represents a peptide chain containing from 2 to 10, preferably from 4 to 6, amino acids, at least one of Pep and of AA<sub>1</sub> containing at least one tyrosine unit.



20. (Currently Amended) The compound as claimed in claim 19, ~~characterized in that wherein~~ Pep contains an arginine-glycine-aspartic acid sequence.

21. (Currently Amended) The compound as claimed in Claim 1, ~~either one of claims 19 and 20, characterized in that it corresponds corresponding~~ to formula B:



Molecule B

22. (Currently Amended) The compound as claimed in Claim 1, ~~any one of claims 1 to 11, characterized in that it corresponds corresponding~~ to formula (Ic):



(Ic)

in which:

AP represents an active principle capable of acting on a biological target;

Pep represents a peptide chain containing from 2 to 10 amino acids;

x represents an integer chosen from 0 and 1;

X represents a peptide chain comprising from 1 to 5 amino acids;

AA<sub>1</sub> represents an amino acid carrying an acid, amine, alcohol or thiol function on its side chain;

Y represents a fluorinated C<sub>4</sub>-C<sub>12</sub> hydrocarbon-based chain containing a function chosen from  $\text{O} \begin{array}{c} \parallel \\ \text{C} \\ \diagdown \end{array}$  -NH, -O-CO-NH-, S and O that allows its attachment either to one of the ends of the amino acid AA<sub>1</sub>, or to the side chain of AA<sub>1</sub>.


23. (Currently Amended) The compound as claimed in claim 22, ~~characterized in that wherein~~ one or more of the conditions below are verified:

Pep is a peptide recognized by  $\alpha V\beta 3$  integrins and AP is an antimitotic agent;



X, Pep or AA<sub>1</sub> contains at least one tyrosine residue;

X represents a chain of 1 to 3 amino acids.

24. (Currently Amended) The compound as claimed in claim 22 or 23, ~~characterized in that it corresponds corresponding~~ to one of formulae C, D and F:



Molecule C (Ara-C)



Molecule F

25. (Currently Amended) The compound as claimed in claim 22, characterized in that AP is adriamycin and X or Pep contain a Gly-Phe-Leu-Gly fragment.

26. (Currently Amended) The compound as claimed in claim 22, characterized in that AP is chosen from melphalan, 5-fluorouracil and imatinib mesylate.

27. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in ~~any one of claims 1 to 11 and 13 to 18~~ Claim 1 in a pharmaceutically acceptable carrier.

28. (Currently Amended) The use of a compound of formula A, C, D or F as claimed in ~~either of claims 16 and 24~~ Claim 16, for preparing a pharmaceutical composition intended to prevent and/or treat cancer.

29. (Original) The use of a compound of formula B as claimed in claim 21, for preparing a pharmaceutical composition intended to detect the presence of cancerous cells.

30. (Original) The use of a compound of formula E as claimed in claim 18, for preparing a pharmaceutical composition intended to prevent and/or treat pathologies associated with oxidative stress and with the formation of oxygenated free-radical species.